We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?-Reference-Cited by-同舟云学术

We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?

Published:2014-01-13 Issue:2 Volume:14 Page:127-130
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Fragoso Yara D,Arruda Niedja M,Arruda Walter O,Brooks Joseph BB,Correa Eber C,Damasceno Alfredo,Damasceno Carlos A,Ferreira Maria LB,Giacomo Maria CB,Gomes Sidney,Gonçalves Marcus VM,Grzesiuk Anderson K,Kaimen-Maciel Damacio R,Lopes Josiane,Machado Suzana CN,Oliveira Celso LS,Stella Carla RAV

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737175.2014.874947

Reference26 articles.

1. Multiple sclerosis

2. Update on Therapeutic Options for Multiple Sclerosis

3. Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis

4. Best practice in the use of natalizumab in multiple sclerosis

5. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study;Neurotherapeutics;2021-04

2. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients;Annals of Neurology;2016-04-20

3. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases;Clinical Therapeutics;2016-03

4. Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis;Expert Review of Clinical Pharmacology;2016-02-21

5. Modifiable environmental factors in multiple sclerosis;Arquivos de Neuro-Psiquiatria;2014-11